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INTRODUCTION:  Cutaneous  metastasis  from  gastric  cancer  is a rare  occurrence.  The linitis  gastric  carci-
noma  accounts  only  8.7%  of all gastric  cancers.
PRESENTATION OF  CASE:  We  report  a  case  of  female  patient  who  was  followed  for  linits  cancer  withvailable online 23 November 2012
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peritoneal  metastasis  treated  by six  cycles  of  chemotherapy.  After  seventeen  months  of  control,  the
relapse  of the  disease  revealed  by  occurrence  of cutaneous  metastatsis.
DISCUSSION: Cutaneous  metastasis  from  linit gastric  is rare  and  the  prognostic  remains  poor.  The  treat-
ment  is  palliative.
CONCLUSION:  This rare  presentation  should  encourage  the  practitioners  to  biopsy  any suspicion  skin
lesion.
gical © 2012 Sur
. Introduction
Cutaneous metastases from gastric cancer are very rare. Skin
epresents a common site for metastases from melanoma, lung,
reast and colon cancers.1 The incidence of cutaneous metastases
f the upper digestive tract carcinomas and of all gastric cancer is
espectively less than 1% and 0.8%.2,3 They can occur as the ﬁrst sign
f the tumour or appear late during the course of the disease.4
We  report the case of a female patient who presented initially
 gastric linitis with peritoneal metastasis treated by six cycles of
pirubicine, Oxaliplatine and capecitabine. A partial response was
rst noted, but seventeen months later she presented a relapse
evealed by cutaneous metastasis.
. Case report
A  71-year-old woman was hospitalized because chronic diar-
hea evolving for four months associated with weight loss of
fteen kilograms during one year. There was no abdominal pain
r rectal syndrome. The clinical examination was  unremarkable.
he endoscopy revealed a non stenotic parietal inﬁltration of the
astric antrum. Histologic analysis found an inﬁltrating adeno-
arcinoma with dissociated cells. The tumour did not express
uman epidermal growth-factor receptor 2. The abdominal com-
uted tomography (CT) scan revealed an invasion of the stomach,
eritoneal carcinomatosis and ascitis (Fig. 1). The computed tomo-
raphy of the thorax and the blood electrolytes were normal. The
ncological markers were elevated: ACE at 44 U/ml and CA 19-9 at
49 U/ml. The disease was staged at IV.
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Our patient was treated by six cycles of chemotherapy includ-
ing Epirubicin 50 mg/m2 intravenous bolus on one day every three
weeks, oxaliplatine (Eloxatin) 130 mg/m2 intravenous over 2 h on
one day every three weeks, and capecitabine (xeloda) 1250 mg/m2
oral continuously. During treatment, she presented a sensitive neu-
ropathy grade I as side effect. A partial response was obtained after 6
cycles, with a gain of weight and a decrease the levels of biomarkers.
After seventeen months of good control of the disease, we  noted
the apparition of nodular lesion of the skin in the ﬂank and the arm
(Fig. 2).
The  lesion was not pruriginous and did not increase in size. An
opinion dermatologic was then requested to identify the nature
of the lesion. The biopsy was  recommended and conﬁrmed the
diagnostic of cutaneous metastasis of gastric linitis (Figs. 3 and 4).
Clinically, the patient is asymptomatic. The computed tomo-
graphy of the thorax and the abdomen found other lesions and
conﬁrmed the progression of the disease. Furthermore, the onco-
logical blood markers were elevated. Subsequently, the patient was
given chemotherapy with irinotecan at a dose of 180 mg per square
(J1) and leucovorine 400 mg  per square, ﬂuoruracil at 400 mg  per
square in bolus and then 2400 mg  per square on 46 h. The patient
receives six cycles of chemotherapy whose tolerance was correct.
After six cycles, taking into account of alteration of the clinical sta-
tus with a performance status 3, we decided to establish a best
supportive care.
3.  Discussion
The cutaneous metastases represent 0.8% of all gastric cancers.3
The linitis gastric carcinoma accounts only 8.7% of all gastric
Open access under CC BY-NC-ND license. cancers.5
A systemic medline database search on pubmed was conducted
using the keywords the following Mesh “stomach neoplasms, skin
metastases”. We  found forty-one cases reported in the literature.
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Fig. 1. Abdomen scanner showed an inﬁltration of the gastric wall with peritoneal
carcinomatosis and ascitis.
F
a
m
f
d
T
F
rig. 2. Photo shows the occurrence a lesion in the arm. It was  nodular, erythematous
nd  well circumscribed with a size of 3 cm.
Among women, Breast cancer is the ﬁrst cause of cutaneous
etastases. The trunk and particulary the umbilical area, is a
avored site.6The term linitis gastric was ﬁrst used by Brinton in 1854 who
escribe a diffuse increase in the connective tissue of the stomach.
hen, H.M. Lyle reported a ﬁrst exaustive study in 1911.7
ig. 3. Skin histology shows an diffuse inﬁltration of subcutaneous tissue by signet
ing tumour (hematoxylin and eosin: magniﬁcation 400×).Fig. 4. Skin histology shows an diffuse inﬂitration of subcutaneous tissue by signet
ring tumour (hematoxylin and eosin: magniﬁcation 40×).
On endoscopic examination, linitis gastric is characterized by
thickened gastric folds and the rigidity of the involved portion of
the stomach. The endoscopic biopsy has a sensibility of 50% only.
Histologically, the linitis gastric corresponds to signet ring cells in
a fribrous stroma.
The  immunohistologic exam must be carried to differenciate
between secondary and primary tumour. The markers which rec-
ommended are GCDFP, PSA, TTF1, and estrogen and progesterone
receptors. Nerverthless, melanoma and lymphoma are the also the
differential diagnosis with signet ring cell carcinoma.8
Typically, linitis gastric is very aggressive disease, it inﬁltrates
the gastric wall with involvement of peritoneum, lymph nodes.
Metastatic of the skin is rare. It can probably be explained by
haematogenous dissemination. No data are available in the liter-
ature regarding the physiopathology.
Cutaneous metastases may  be the ﬁrst indication of gastric
cancer, but they can also occur some months or years after the diag-
nosis of the disease.9 In our case, the metastases are metachronous
and they revealed the progression of the disease.
Clinically, as comparing with skin metastasis of the other can-
cer, we note no difference concerning the characteristic of the
lesion. They usually appear as a single or multiples nodules, show-
ing zosteriform or allergic contact dermatitis-like aspect, or as
erysipelatoides carcinoma or cellulitis-like patterns.
The treatment of metastatic linitis gastric is palliative. The
chemotherapeutic agents used 5-ﬂuorouracil, cisplatine and adri-
amycine. About twenty of patients with failure of ﬁrst line
chemotherapy receive second line chemotherapy. It is based on
trastuzumab with active chemotherapy with cisplatin and ﬂuo-
ropyridine for patients who are HER 2-neu positive, if not used as
ﬁrst line therapy.10
Irinotecan improves survival compared with best supportive
care in patients with advanced gastric cancers who progress within
six months after ﬁrst line chemotherapy (median 4.0 versus 2.4
months; P = 0.023), Furthermore, Docetaxel and Paclitaxel show an
activity with a response of 20%. For the patients who relapse > 3
months after ﬁrst line chemotherapy, we can discuss with the
patient the same treatment used in ﬁrst line.11
Skin metastases are still a sign of poor prognosis. Indeed, Bordin
and Weitzner reported that the duration of survival from the time
of diagnosis of metastatic carcinoma in the skin is about 11.4 weeks,
with a range of 2–34 weeks.12 The treatment is palliative.
For our case, there is an interval of twenty weeks since the diag-
nosis of the cutaneous metastasis.4.  Conclusion
In conclusion, we reported an unusual case of gastric cancer
which was  treated and showed an arm and ﬂank skin relapse
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fter seventeen months. This should encourage the practitioners
o biopsy any suspicious skin lesion in patients with cancer history.
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